Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda

Questex's Fierce Life Sciences announced the agenda for the 16th annual PODD (Partnership Opportunities in Drug Delivery) Conference, scheduled for October 29-30, 2026, in Boston. The event will gather over 1,000 industry executives and features 150+ sessions with keynotes from Regeneron's Dr. George Yancopoulos and MIT's Dr. Robert Langer, covering topics including AI in drug delivery, pharma partnering strategies, and reimbursement challenges.

06/23/2026, 8:00 AM • GlobeNewswire

Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight

The cutaneous lupus erythematosus (CLE) market is projected to grow at 8% CAGR through 2036, driven by emerging targeted therapies and increased disease awareness. The market was valued at USD 650 million in 2025 across seven major markets. Key pipeline drugs from major pharmaceutical companies targeting plasmacytoid dendritic cells and type I interferon pathways are expected to transform treatment options for CLE patients.

06/22/2026, 1:00 PM • GlobeNewswire

Moderna Has Some Key Approvals Ahead. Is the Stock a Buy?

Moderna's stock has surged over 100% this year as the company diversifies beyond COVID-19 vaccines using its mRNA platform. Key catalysts include FDA approval of mFlusiva (flu vaccine) expected August 5, 2026, and the European Commission's approval of mCOMBRIX (flu-COVID combination vaccine). The company's most transformative opportunity lies in cancer vaccines, with phase 3 data for mRNA-4157 expected later in 2026. Despite 260% revenue growth in Q1 2026, Moderna remains unprofitable but has $7.5 billion in cash and targets company-wide breakeven by 2028.

06/20/2026, 7:30 AM • The Motley Fool

Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook

Pfizer stock fell 2.74% following the announcement that CFO Dave Denton will depart in August, raising investor concerns about leadership continuity and the company's ability to meet 2026 guidance. While recent drug approvals strengthen the pipeline, the CFO transition creates uncertainty around financial execution and earnings recovery.

06/18/2026, 7:09 PM • The Motley Fool

Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape

DelveInsight's 2026 report reveals a robust AMD clinical trial pipeline with 90+ active players developing 100+ pipeline drugs across various clinical stages. The report highlights promising therapies including elamipretide, 4D-150, MK-8748, and SAR402663, with approximately 15+ drugs in late-stage development. Recent advances include Merck's Phase IIb/III trial initiation for MK-8748, 4D Molecular Therapeutics' Phase III enrollment completion for 4D-150, and FDA fast-track designation for SAR402663.

06/18/2026, 1:00 PM • GlobeNewswire

FDA Expands Merck Pneumococcal Shot Label To Include At-Risk Children And Teens

The FDA approved an expanded indication for Merck's Capvaxive pneumococcal vaccine, extending its use to children and adolescents ages 2-17 with chronic conditions. The approval was based on Phase 3 STRIDE-13 trial data and makes Capvaxive the only pneumococcal conjugate vaccine specifically studied and indicated for this patient group in the U.S. The vaccine covers serotypes associated with approximately 79% of invasive pneumococcal disease cases among at-risk children.

06/18/2026, 11:29 AM • Benzinga

[Latest] Global GLP-1 Receptor Agonist Market Size/Share Worth USD 95.3 Billion by 2035 at a 12.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global GLP-1 receptor agonist market, valued at USD 28.7 billion in 2025, is projected to grow to USD 95.3 billion by 2035 at a 12.1% CAGR. Growth is driven by rising type 2 diabetes and obesity cases, technological innovations including oral formulations, and expanded insurance coverage. North America leads the market while Asia Pacific shows the highest growth rate.

06/16/2026, 6:30 PM • GlobeNewswire

3 Dividend Stocks to Hold for the Long Haul

The article recommends three healthcare dividend stocks for long-term investors: Bristol Myers Squibb, Merck, and Medtronic. Despite facing recent challenges like patent cliffs and competitive pressures, all three companies have strong dividend track records with consistent payout increases and promising pipelines to drive future growth.

06/16/2026, 6:15 AM • The Motley Fool

Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight

The metastatic prostate cancer market is projected to experience robust growth through 2036, valued at USD 11.5 billion in 2025 across seven major markets. The market is transitioning from conventional androgen deprivation therapy toward combination-based, biomarker-driven approaches, with novel therapies such as PSMA-targeted radioligand therapies and PARP inhibitors reshaping the treatment paradigm. Key emerging drugs include 225Ac-PSMA-617, 177Lu-DOTA-rosopatamab, and cabozantinib, with multiple pharmaceutical companies advancing innovative treatments in clinical trials.

06/10/2026, 1:00 PM • GlobeNewswire

Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial

Gilead Sciences and Merck discontinued their Phase 3 KEYNOTE-D46/EVOKE-03 trial evaluating Trodelvy plus Keytruda for lung cancer after the combination failed to reach statistical significance in progression-free survival with low probability of overall survival benefit. However, the companies reported positive Phase 3 results for an investigational once-weekly oral HIV regimen combining islatravir and lenacapavir, which met its primary efficacy endpoints in two studies.

06/09/2026, 1:44 PM • Benzinga

Lilly Just Announced 3 Infectious Disease Acquisitions in 1 Day. Is This the Beginning of Its Post-Obesity Growth Strategy?

Eli Lilly announced three infectious disease acquisitions in a single day—Curevo (shingles vaccine), LimmaTech Biologics (bacterial pathogen vaccines), and Vaccine Company (viral infection prevention)—totaling over $3.8 billion. These deals signal management's strategy to diversify beyond its blockbuster obesity drugs (Zepbound and Mounjaro) and build new growth engines focused on disease prevention, particularly addressing antimicrobial resistance and infections linked to serious conditions like multiple sclerosis and cancer.

06/08/2026, 5:23 PM • The Motley Fool

Global Sustainability Awards 2026 Opens Final Call for Entries as Industry Leaders Prepare to Celebrate Sustainability Excellence

The Global Sustainability Awards 2026 has announced a final call for entries, closing on 29th June 2026. The awards ceremony will take place on 8th September in London, celebrating sustainability excellence across six categories. The judging panel includes Chief Sustainability Officers from major global organizations including Google, Merck, RELX, Schneider Electric, and the BBC.

06/02/2026, 9:00 AM • GlobeNewswire

Moderna Reports Strong 5-Year Cancer Vaccine Data, Expands CEPI Partnership; Stock Falls

Moderna announced positive five-year follow-up results from its Phase 2b trial showing its melanoma vaccine candidate (intismeran autogene plus KEYTRUDA) reduced recurrence or death risk by 49% compared to KEYTRUDA alone. The company also expanded its partnership with CEPI to develop a Bundibugyo ebolavirus vaccine, with CEPI committing up to $50 million. Despite the positive news, Moderna's stock fell 2.78% to $45.88.

06/01/2026, 12:39 PM • Benzinga

Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%

RTW Investments purchased 16,010,524 shares of Erasca for approximately $189.23 million in Q1 2026, with the position's value rising to $261.42 million by quarter-end. The clinical-stage biotech company, which develops oral inhibitors targeting the RAS/MAPK pathway for cancer treatment, has seen its stock surge 800% over the past year. The investment reflects confidence in Erasca's lead program ERAS-0015, which showed encouraging early data in KRAS-driven cancers, and the company's strong cash position of $408.5 million expected to fund operations into late 2028.

05/29/2026, 8:27 PM • The Motley Fool

Glioblastoma Multiforme Market Poised for Significant Growth at a CAGR of 13.2% During the Forecast Period (2026–2036), as Next-Generation Therapies Enter Late-Stage Development | DelveInsight

The glioblastoma multiforme market is expected to grow at a CAGR of 13.2% from 2026-2036, driven by next-generation therapies entering late-stage development. The market was valued at USD 900 million in 2025 across the 7MM, with approximately 38,000 incident cases. Key players including Avita Biomedical, Kazia Therapeutics, Laminar Pharma, and others are advancing innovative immunotherapies, targeted treatments, and personalized medicine approaches to address the poor prognosis of this aggressive brain tumor.

05/27/2026, 1:00 PM • GlobeNewswire